Nitric Oxide

Identification

Summary

Nitric Oxide is a vasodilating agent used in the treatment of hypoxic respiratory failure in premature neonates.

Brand Names
Inomax, Kinox, Noxivent
Generic Name
Nitric Oxide
DrugBank Accession Number
DB00435
Background

Nitric oxide or Nitrogen monoxide is a chemical compound with chemical formula NO. This gas is an important signaling molecule in the body of mammals including humans and is an extremely important intermediate in the chemical industry. It is also a toxic air pollutant produced by automobile engines and power plants.

Nitric oxide (NO) should not be confused with nitrous oxide (N2O), a general anaesthetic, or with nitrogen dioxide (NO2) which is another poisonous air pollutant.

The nitric oxide molecule is a free radical, which is relevant to understanding its high reactivity. It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 30.0061
Monoisotopic: 29.997988627
Chemical Formula
NO
Synonyms
  • EDRF
  • endothelium-derived relaxing factor
  • Mononitrogen monoxide
  • Monóxido de nitrógeno
  • Monoxyde d'azote
  • Nitric Oxide
  • Nitrogen monooxide
  • Nitrogen monoxide
  • Nitrosyl
  • NO
  • óxido de nitrógeno(II)
  • óxido nítrico
  • Oxyde azotique
  • Oxyde nitrique
  • Stickstoff(II)-oxid
  • Stickstoffmonoxid
External IDs
  • OHM-11771

Pharmacology

Indication

For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofHypoxic respiratory failure•••••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale. In neonates with PPHN, Nitric oxide improves oxygenation (as indicated by significant increases in PaO2). Nitric oxide appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better entilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.

Mechanism of action

Nitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide produces pulmonary vasodilation.

TargetActionsOrganism
AGuanylate cyclase soluble subunit alpha-2
inducer
Humans
UMetallothionein-1ANot AvailableHumans
UIndoleamine 2,3-dioxygenase 1Not AvailableHumans
UNitric oxide synthase, endothelial
product of
Humans
Absorption

Nitric oxide is absorbed systemically after inhalation.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

via pulmonary capillary bed

Route of elimination

Nitrate has been identified as the predominant nitric oxide metabolite excreted in the urine, accounting for >70% of the nitric oxide dose inhaled.

Half-life

2–6 seconds

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency)Disease
Creatine Deficiency, Guanidinoacetate Methyltransferase DeficiencyDisease
Hyperornithinemia with Gyrate Atrophy (HOGA)Disease
Arginine and Proline MetabolismMetabolic
Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency)Disease
Hyperprolinemia Type IIDisease
Hyperprolinemia Type IDisease
L-Arginine:Glycine Amidinotransferase DeficiencyDisease
Prolidase Deficiency (PD)Disease
Prolinemia Type IIDisease
Ornithine Aminotransferase Deficiency (OAT Deficiency)Disease
Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-syndrome]Disease
Nitric Oxide Signaling PathwaySignaling
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirNitric Oxide may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbaloparatideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Abaloparatide.
AcebutololThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Acebutolol.
AceclofenacAceclofenac may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
GenosylGas0.98 mg/1LRespiratory (inhalation)VERO BIOTECH, INC.2019-12-20Not applicableUS flag
GenosylGas0.98 mg/1LRespiratory (inhalation)VERO BIOTECH, INC.2022-12-28Not applicableUS flag
InomaxInhalant800 ppmRespiratory (inhalation)Linde Healthcare Ab2016-09-08Not applicableEU flag
InomaxGas800 ppm / cylrRespiratory (inhalation)INO Therapeutics2005-11-23Not applicableCanada flag
InomaxInhalant400 ppmRespiratory (inhalation)Linde Healthcare Ab2016-09-08Not applicableEU flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Noxivent 101Gas100 mg/1LRespiratory (inhalation)Linde Gas & Equipment Inc2018-10-04Not applicableUS flag
Noxivent 102Gas800 mg/1LRespiratory (inhalation)Linde Gas & Equipment Inc2018-10-04Not applicableUS flag
UlspiraGas0.8 mL/100LRespiratory (inhalation)Airgas Therapeutics, LLC2023-08-04Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
695801540Liquid400 mg/500mgTopicalHumanEnos LLC2023-02-142024-02-13US flag
Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)Capsule400 mg/500mgTopicalHumanEnos LLC2024-02-132025-02-12US flag
Bio NO more Joint Pain (Helps improve osteoarthritis and Immunity, Soybean and oplopanax elatus Nakai fermented powder)Capsule100 mg/800mgTopicalHumanEnos LLC2023-02-142024-02-13US flag
Bio NO more Joint Pain (Helps improve osteoarthritis and immunity, Soybean fermented powder and Oplopanax elatus nakai extract powder)Capsule100 mg/800mgTopicalHumanEnos LLC2024-02-132025-02-12US flag
Bio NO more Menopause (Helps improve menopouse and Immunity, Soybean fermented powder)Capsule100 mg/480mgTopicalHumanEnos LLC2024-02-132025-02-12US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
695801540Nitric Oxide (400 mg/500mg)LiquidTopicalHumanEnos LLC2023-02-142024-02-13US flag
Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)Nitric Oxide (400 mg/500mg)CapsuleTopicalHumanEnos LLC2024-02-132025-02-12US flag
Bio NO more Joint Pain (Helps improve osteoarthritis and Immunity, Soybean and oplopanax elatus Nakai fermented powder)Nitric Oxide (100 mg/800mg)CapsuleTopicalHumanEnos LLC2023-02-142024-02-13US flag
Bio NO more Joint Pain (Helps improve osteoarthritis and immunity, Soybean fermented powder and Oplopanax elatus nakai extract powder)Nitric Oxide (100 mg/800mg)CapsuleTopicalHumanEnos LLC2024-02-132025-02-12US flag
Bio NO more Menopause (Helps improve menopouse and Immunity, Soybean fermented powder)Nitric Oxide (100 mg/480mg)CapsuleTopicalHumanEnos LLC2024-02-132025-02-12US flag

Categories

ATC Codes
R07AX01 — Nitric oxide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as other non-metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen belongs to the class of 'other non-metals'.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Other non-metal organides
Sub Class
Other non-metal oxides
Direct Parent
Other non-metal oxides
Alternative Parents
Inorganic oxides
Substituents
Inorganic oxide / Other non-metal oxide
Molecular Framework
Not Available
External Descriptors
reactive nitrogen species, reactive oxygen species, nitrogen oxide, inorganic radical (CHEBI:16480)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
31C4KY9ESH
CAS number
10102-43-9
InChI Key
MWUXSHHQAYIFBG-UHFFFAOYSA-N
InChI
InChI=1S/NO/c1-2
IUPAC Name
nitroso
SMILES
[N]=O

References

Synthesis Reference

Stephen M. Campbell, Chen-Youn Sue, "Nitric oxide for vapor phase elimination of styrene and acrylonitrile popcorn polymer in bulk SAN production." U.S. Patent US5272231, issued November, 1968.

US5272231
General References
  1. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 Jan;87(1):315-424. [Article]
  2. FDA Approved Drug Products: Inomax (nitric oxide) gas for inhalation [Link]
Human Metabolome Database
HMDB0003378
KEGG Drug
D00074
KEGG Compound
C00533
PubChem Compound
145068
PubChem Substance
46506897
ChemSpider
127983
RxNav
7442
ChEBI
16480
ChEMBL
CHEMBL1200689
Therapeutic Targets Database
DAP001056
PharmGKB
PA450635
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Nitric_oxide
MSDS
Download (52.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticPremature Births1
4CompletedOtherHeart Transplant Surgery / Lung Transplant Surgery1
4CompletedTreatmentHeart Failure1
4CompletedTreatmentInfants / Persistent foetal circulation disorders / Respiratory Failure1
4Not Yet RecruitingTreatmentHernias, Diaphragmatic, Congenital1

Pharmacoeconomics

Manufacturers
  • Ino therapeutics inc
Packagers
  • Ino Therapeutics Inc.
  • Pulmonox Gas Corporation
Dosage Forms
FormRouteStrength
LiquidTopical400 mg/500mg
CapsuleTopical400 mg/500mg
CapsuleTopical100 mg/800mg
CapsuleTopical100 mg/480mg
TabletTopical100 mg/900mg
CapsuleTopical100 mg/350mg
GasRespiratory (inhalation)99 %
SoapTopical50 mg/100mg
LiquidTopical100 mg/200mg
LiquidTopical40 mg/50mg
LiquidTopical100 mg/300mg
LiquidTopical12 mg/14mg
LiquidTopical10 mg/100mg
LiquidTopical30 mg/50mg
LiquidTopical12 mg/120mg
LiquidTopical10 mg/50mg
LiquidTopical30 mg/40mg
LiquidTopical8 mg/10mg
LiquidTopical50 mg/100mg
LiquidTopical15 mg/150mg
LiquidTopical20 mg/30mg
CapsuleTopical100 mg/250mg
GasRespiratory (inhalation)2.52 g
CapsuleTopical500 mg/500mg
GasRespiratory (inhalation)0.08 % v/v
Gas
GasRespiratory (inhalation)0.123 mg/1L
GasRespiratory (inhalation)0.98 mg/1L
GasRespiratory (inhalation)100 ppm / cylr
GasRespiratory (inhalation)6 mg/1L
GasRespiratory (inhalation)800 ppm / cylr
InhalantRespiratory (inhalation)400 ppm
InhalantRespiratory (inhalation)800 ppm
GasRespiratory (inhalation)1000 ppm
GasRespiratory (inhalation)225 ppm
GasRespiratory (inhalation)450 ppm
GasRespiratory (inhalation)
LiquidTopical100 mg/150mg
CapsuleTopical100 mg/400mg
CapsuleTopical100 mg/420mg
LiquidTopical10 mg/20mg
LiquidTopical5 mg/10mg
LiquidTopical1.1157 g/100mL
GasRespiratory (inhalation)0.02 %
GasRespiratory (inhalation)0.8 mL
GasRespiratory (inhalation)100 mg/1L
GasRespiratory (inhalation)800 mg/1L
GasRespiratory (inhalation)100 g
LiquidTopical100 mg/500mg
GasRespiratory (inhalation)
GasRespiratory (inhalation)800 ppm
TabletTopical100 mg/500mg
GasRespiratory (inhalation)0.8 mL/100L
GasEndotracheal
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5485827No1996-01-232013-01-23US flag
CA2186892No2007-11-272015-04-03Canada flag
US5732693Yes1998-03-312017-06-13US flag
US5752504Yes1998-05-192017-06-13US flag
US8282966Yes2012-10-092029-12-30US flag
US8291904Yes2012-10-232031-07-06US flag
US8293284Yes2012-10-232029-12-30US flag
US8431163Yes2013-04-302029-12-30US flag
US8776794Yes2014-07-152031-07-06US flag
US8776795Yes2014-07-152031-07-06US flag
US8573210Yes2013-11-052031-07-06US flag
US8795741Yes2014-08-052029-12-30US flag
US8846112Yes2014-09-302029-12-30US flag
US6125846Yes2000-10-032017-11-16US flag
US9265911Yes2016-02-232031-07-06US flag
US9295802Yes2016-03-292031-07-06US flag
US9279794Yes2016-03-082034-08-19US flag
US8573209Yes2013-11-052031-07-06US flag
US9408993Yes2016-08-092031-07-06US flag
US9770570Yes2017-09-262036-11-03US flag
US9604028No2017-03-282029-08-13US flag
US10213572No2019-02-262036-02-12US flag
US7618594No2009-11-172026-10-17US flag
US7560076No2009-07-142027-04-21US flag
US6758214No2004-07-062022-02-23US flag
US10737051No2020-08-112035-10-20US flag
US8609028No2013-12-172025-08-18US flag
US9956373No2018-05-012025-08-18US flag
US10814092No2020-10-272025-10-17US flag
US7947227No2011-05-242026-10-17US flag
US8057742No2011-11-152026-01-18US flag
US8226916No2012-07-242025-08-18US flag
US10124142No2018-11-132025-08-18US flag
US8821801No2014-09-022025-08-18US flag
US8607785No2013-12-172030-07-14US flag
US9522249No2016-12-202025-08-18US flag
US9701538No2017-07-112029-01-28US flag
US8944049No2015-02-032029-08-13US flag
US10926054No2021-02-232029-08-13US flag
US11103669No2021-08-312030-06-21US flag
US11291793No2005-08-182025-08-18US flag
US11383059No2005-08-182025-08-18US flag
US11511252No2009-09-212029-09-21US flag
US11554241No2005-08-182025-08-18US flag
US11672938No2020-07-222040-07-22US flag

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)-163.6 °CPhysProp
boiling point (°C)-151.7 °CPhysProp
water solubility9.49E+004 mg/LNot Available
logP0Not Available
Predicted Properties
PropertyValueSource
logP-0.35Chemaxon
pKa (Strongest Basic)-2.9Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area34.14 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity2.89 m3·mol-1Chemaxon
Polarizability1.69 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9785
Caco-2 permeable+0.6149
P-glycoprotein substrateNon-substrate0.9034
P-glycoprotein inhibitor INon-inhibitor0.957
P-glycoprotein inhibitor IINon-inhibitor0.9892
Renal organic cation transporterNon-inhibitor0.8973
CYP450 2C9 substrateNon-substrate0.8884
CYP450 2D6 substrateNon-substrate0.888
CYP450 3A4 substrateNon-substrate0.7535
CYP450 1A2 substrateNon-inhibitor0.7402
CYP450 2C9 inhibitorNon-inhibitor0.9383
CYP450 2D6 inhibitorNon-inhibitor0.896
CYP450 2C19 inhibitorNon-inhibitor0.8796
CYP450 3A4 inhibitorNon-inhibitor0.9754
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8945
Ames testAMES toxic0.5342
CarcinogenicityCarcinogens 0.8336
BiodegradationReady biodegradable0.9371
Rat acute toxicity2.5108 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8524
hERG inhibition (predictor II)Non-inhibitor0.9756
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (6.86 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-001i-9000000000-d182bfca83d886821e6d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-4faa0e3c79683567bab0
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-4faa0e3c79683567bab0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-4faa0e3c79683567bab0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-4faa0e3c79683567bab0
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-4faa0e3c79683567bab0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-4faa0e3c79683567bab0
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-108.68115
predicted
DeepCCS 1.0 (2019)
[M-H]-108.68115
predicted
DeepCCS 1.0 (2019)
[M+H]+110.43489
predicted
DeepCCS 1.0 (2019)
[M+H]+110.43489
predicted
DeepCCS 1.0 (2019)
[M+Na]+117.18667
predicted
DeepCCS 1.0 (2019)
[M+Na]+117.18667
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inducer
General Function
Heme binding
Specific Function
Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.
Gene Name
GUCY1A2
Uniprot ID
P33402
Uniprot Name
Guanylate cyclase soluble subunit alpha-2
Molecular Weight
81749.185 Da
References
  1. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109-42. [Article]
  2. Mancuso C, Navarra P, Preziosi P: Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem. 2010 May;113(3):563-75. doi: 10.1111/j.1471-4159.2010.06606.x. Epub 2010 Jan 20. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
Gene Name
MT1A
Uniprot ID
P04731
Uniprot Name
Metallothionein-1A
Molecular Weight
6120.19 Da
References
  1. Aravindakumar CT, Ceulemans J, De Ley M: Nitric oxide induces Zn2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. Biochem J. 1999 Nov 15;344 Pt 1:253-8. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tryptophan 2,3-dioxygenase activity
Specific Function
Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway (PubMed:17671174). Involved in the peripheral immune tolerance, cont...
Gene Name
IDO1
Uniprot ID
P14902
Uniprot Name
Indoleamine 2,3-dioxygenase 1
Molecular Weight
45325.89 Da
References
  1. Samelson-Jones BJ, Yeh SR: Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Product of
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induce...
Gene Name
NOS3
Uniprot ID
P29474
Uniprot Name
Nitric oxide synthase, endothelial
Molecular Weight
133287.62 Da
References
  1. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM, Dimmeler S: Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res. 2002 Nov 1;91(9):837-44. doi: 10.1161/01.res.0000037983.07158.b1. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Electron carrier activity
Specific Function
Not Available
Gene Name
ALDH2
Uniprot ID
P05091
Uniprot Name
Aldehyde dehydrogenase, mitochondrial
Molecular Weight
56380.93 Da
References
  1. Moon KH, Kim BJ, Song BJ: Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation. FEBS Lett. 2005 Nov 7;579(27):6115-20. Epub 2005 Oct 11. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Nakano R, Sato H, Watanabe A, Ito O, Shimizu T: Conserved Glu318 at the cytochrome P450 1A2 distal site is crucial in the nitric oxide complex stability. J Biol Chem. 1996 Apr 12;271(15):8570-4. [Article]
  2. Mulero-Navarro S, Santiago-Josefat B, Pozo-Guisado E, Merino JM, Fernandez-Salguero PM: Down-regulation of CYP1A2 induction during the maturation of mouse cerebellar granule cells in culture: role of nitric oxide accumulation. Eur J Neurosci. 2003 Oct;18(8):2265-72. [Article]
  3. Donato MT, Guillen MI, Jover R, Castell JV, Gomez-Lechon MJ: Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes. J Pharmacol Exp Ther. 1997 Apr;281(1):484-90. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Aitken AE, Lee CM, Morgan ET: Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med. 2008 Mar 15;44(6):1161-8. doi: 10.1016/j.freeradbiomed.2007.12.010. Epub 2007 Dec 23. [Article]
  2. Lee CM, Tripathi S, Morgan ET: Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system. Free Radic Biol Med. 2017 Jul;108:478-486. doi: 10.1016/j.freeradbiomed.2017.04.015. Epub 2017 Apr 17. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Watabe M, Isogai Y, Numazawa S, Yoshida T: Role of c-Myc in nitric oxide-mediated suppression of cytochrome P450 3A4. Life Sci. 2003 Nov 21;74(1):99-108. [Article]

Drug created at June 13, 2005 13:24 / Updated at March 18, 2024 16:48